Capecitabine is an oral prodrug of fluorouracil that is approved for the treatment of advanced breast cancer, but not for neoadjuvant or adjuvant treatment of
3%, respectively) in the
FDA News Release FDA Approves First New Drug Under International Collaboration, A Treatment Option for Patients with HER2-Positive Metastatic Breast
Processa Pharmaceuticals Announces Successful Completion of Phase 1b Safety Evaluation of NGC-Cap in Patients with Advanced Cancer Resulting in
The AUC of capecitabine and its metabolite 5’-DFCR increases proportionally over a dosage range of 500 mg/m 2 /day to 3,500 mg/m 2 /day (0
S
WARNING: XELODA-WARFARIN INTERACTION
On December 16, 2020, FDA approved margetuximab-cmkb (MARGENZA, MacroGenics) Randomization was stratified by chemotherapy choice (capecitabine, eribulin, gemcitabine, or vinorelbine), number On March 13, 2007, the U
Common Xeloda side effects may include: nausea, vomiting, diarrhea, stomach pain; feeling weak or tired; hand and foot syndrome; or
However, a prespecified subgroup analysis showed a significant survival benefit with capecitabine among patients with non–basal-like triple-negative breast cancer (ie, IHC-negative for EGFR and CK5/6)
It is used as a treatment for different types of cancer, including bowel cancer
Current indications include advanced, metastatic breast cancer and colorectal cancers, usually after failure of first line therapies
©2018, Magellan Rx Management NDC: Xeloda 150 mg tablets - 00004-1100-xx Xeloda 500 mg tablets - 00004-1101-xx Generics available from various manufacturers VII
10903 New Hampshire Avenue Silver Spring, MD 20993 Ph
Dose is within FDA maximum limit for any FDA approved indication or is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence)
without your doctor's approval
Approval Letter; Label; Medical Review; Statisical Review XELODA safely and effectively
5 8
1 Colorectal Cancer Capecitabine is an oral prodrug of 5-fluorouracil (5-FU) which is converted to 5FU by a series of reactions catalyzed by different enzymes, the last of the enzymes being thymidine phosphorylase (TP)
Under the terms of the agreement, Cheplapharm will receive product rights for Xeloda ® in certain countries worldwide including the USA